Karyopharm announces upcoming presentations of phase 3 siendo study of selinexor in patients with advanced or recurrent endometrial cancer

Study results to be presented at the european society of medical oncology's  virtual plenary and the society for gynecologic oncology 2022 annual meeting on women's cancer company to host investor conference call on march 17 th at 4:30 pm et newton, mass. , march 16, 2022 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that results from the phase 3 siendo study will be presented at the european society of medical oncology's (esmo) virtual plenary taking place on thursday, march 17, 2022.
KPTI Ratings Summary
KPTI Quant Ranking